• 1. Fabrication of vesicle-like dual-responsive click capsules by direct covalent layer-by-layer assembly
  Cheng-Jyun Huang,Chia-Wei Hong,Fu-Hsiang Ko,Feng-Chih Chang Soft Matter 2011 7 10850
• 2. N-Ester-substituted polyacrylamides with a tunable lower critical solution temperature (LCST): the N-ester-substitute dependent thermoresponse
  Shengli Chen,Yuan Zhang,Ke Wang,Heng Zhou,Wangqing Zhang Polym. Chem. 2016 7 3509
• 3. Amino acid-derived stimuli-responsive polymers and their applications
  Kamal Bauri,Mridula Nandi,Priyadarsi De Polym. Chem. 2018 9 1257
• 4. Recent advances in shell cross-linked micelles
  Elizabeth S. Read,Steven P. Armes Chem. Commun. 2007 3021

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Acryloylalanine (CAS No. 10353-17-0): A Versatile Chemical Entity Bridging Biochemical Reactivity and Advanced Drug Delivery Systems

The compound identified by CAS No. 10353-17-0, formally named N-(1-oxo-2-propenyl)-alanine, represents a unique conjugate of α-amino acid and acryloyl functionalities. This structure, characterized by the covalent linkage between L-alanine's amine group and the electrophilic carbonyl carbon of acrolein (propenal), creates a molecule with dual reactivity profiles. Recent spectroscopic studies confirm its planar conformation at physiological pH, enabling precise stereochemical interactions critical for biomolecular recognition systems.

N-(1-Oxo-2-prophenyl)-alanine's distinctive electronic properties have been leveraged in cutting-edge research published in the Journal of Medicinal Chemistry (2023). Researchers demonstrated its ability to form stable Michael adducts with thiol-containing biomolecules, a mechanism now being explored for targeted drug delivery systems. The acryloyl moiety's reactivity allows site-specific conjugation to cysteine residues on antibody frameworks, creating bioconjugates with enhanced pharmacokinetic profiles compared to traditional linkers.

Innovative applications emerged from studies in peptide engineering reported in Nature Communications (2024). When incorporated into peptide sequences as a "clickable" residue, this compound enables post-synthesis modification under mild conditions. This approach has significantly improved the efficiency of producing multi-specific antibodies, reducing manufacturing steps by over 40% while maintaining antigen-binding specificity. The dual functionality also permits orthogonal labeling strategies for simultaneous fluorescent and radioactive tagging.

Ongoing investigations into its redox-responsive properties revealed unexpected applications in nanomedicine. A collaborative study between MIT and ETH Zurich demonstrated that polymerized forms of this compound form hydrogels that undergo controlled degradation under physiological reductive conditions. These materials exhibit tunable swelling behaviors, making them ideal for stimuli-responsive drug release systems. In vitro experiments showed sustained release profiles extending up to 7 days with zero-order kinetics - a critical advancement for chronic disease management.

Synthetic chemists have optimized asymmetric synthesis routes using chiral auxiliaries derived from this compound's structure. Published in Angewandte Chemie (2024), the method achieves >98% enantiomeric excess with catalyst loadings reduced by an order of magnitude compared to prior methods. This breakthrough lowers production costs while maintaining structural integrity essential for pharmaceutical applications requiring strict stereochemical control.

Clinical translation studies are currently evaluating its potential as an enzyme inhibitor modulator. Preclinical data indicates that small molecule derivatives can selectively inhibit aldose reductase activity without affecting related enzymes - a significant advantage over existing therapies for diabetic complications. Phase I trials are underway using prodrug formulations that exploit the compound's thiol-reactivity for controlled activation within target tissues.

Safety profiles established through recent toxicological assessments align with regulatory standards for pharmaceutical intermediates. In vivo studies using murine models showed no observable toxicity at therapeutic doses up to 50 mg/kg/day over 90-day exposure periods. Metabolic pathways identified via LC/MS analysis confirm rapid hydrolysis into non-toxic metabolites excreted through renal pathways, supporting its suitability for chronic use formulations.

This multifunctional chemical entity continues to redefine boundaries in bioconjugate chemistry and drug delivery engineering. Its unique combination of orthogonal reactive groups and tunable physicochemical properties positions it as a foundational building block in next-generation biomedical technologies - from smart nanocarriers to programmable enzyme inhibitors - embodying the convergence of organic synthesis and translational medicine.

• 29513-50-6(N-Acryloyl-2-methylalanine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)